COVID-19 Vaccines: Novavax Gets Reprieve With US FDA Panel Supporting JN.1 Formulation

 
• By Sue Sutter

Advisory committee members said having Novavax’s protein-based vaccine available in the fall was important, but would not have been possible if a different variant strain were used. They also worried separate recommendations by vaccine type would cause confusion.

Tree trunk
A JN.1 vaccine will target the trunk of the tree, not the branches, a CDC official said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers